Multidrug Resistant Bacteria Global Market Report 2024

The global multidrug resistant bacteria market has grown strongly in recent years. It will grow from $11.86 billion in 2023 to $12.61 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to antibiotic resistance crisis, advancements in drug discovery, regulatory incentives, public health initiatives.

The global multidrug resistant bacteria market is expected to see strong growth in the next few years. It will grow to $16.22 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to antibiotic stewardship programs, global spread of resistance, phage therapy and alternative treatments, public and private investment. Major trends in the forecast period include precision medicine for infectious diseases, combination therapies, continuous surveillance and monitoring, global collaboration.

The rising prevalence of infectious diseases is expected to drive the growth of the multidrug-resistant bacteria market in the future. Infectious diseases encompass illnesses caused by harmful microorganisms like bacteria, viruses, fungi, or parasites. Multidrug-resistant bacteria are closely linked to infectious diseases because they can lead to infections that are challenging to treat with conventional antibiotics. These bacteria have developed resistance to multiple antibiotics, reducing their susceptibility to commonly used medications for bacterial infections. For instance, data from the Australian Institute of Health and Welfare (AIHW), an Australian government agency, revealed that the number of notifiable infectious diseases in Australia increased from 289,013 in 2020 to 701,820 in 2021. Therefore, the growing prevalence of infectious diseases will be a driving force behind the multidrug-resistant bacteria market.

The complexity of infections is impeding the growth of the multidrug-resistant bacteria market during the forecast period. Infections caused by multidrug-resistant (MDR) bacteria can be more severe and challenging to treat compared to infections caused by susceptible bacteria. This complexity can result in extended hospital stays, increased healthcare costs, and poorer patient outcomes. For instance, a report published in the Lancet, a UK-based peer-reviewed journal, in February 2022 suggested that by 2050, antimicrobial resistance (AMR) might be responsible for up to 10 million annual deaths. Therefore, the impact of infection complexity is presenting a hindrance to the growth of the multidrug-resistant bacteria market.

Major companies operating in the multidrug-resistant bacteria market are placing a strong emphasis on the development of innovative drugs and securing approvals to address the needs of a new segment of consumers. The approval of drugs designed to combat multidrug-resistant bacteria is crucial in the ongoing fight against antibiotic resistance. For example, in May 2023, Entasis Therapeutics Inc., a US-based biotech company, achieved approval from the Food and Drug Administration (FDA) for Xacduor, a combination antibiotic formulated to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VAP) caused by acinetobacter baumannii, a particularly challenging pathogen to treat. Xacduor consists of a combination of ceftolozane and tedizolid phosphate. Ceftolozane is a cephalosporin antibiotic, while tedizolid phosphate belongs to the oxazolidinone class of antibiotics. This approval provides a new treatment option for patients infected with Acinetobacter baumannii who have not responded to other therapies. It can be administered via injection and combines the antibiotic beta-lactam sulbactam with the broad-spectrum beta-lactamase inhibitor durlobactam, reducing acinetobacter resistance and enabling the antibiotic to effectively combat the infection.

In July 2022, Innoviva Inc., a US-based pharmaceutical company, acquired Entasis Therapeutics Inc. for an undisclosed amount. This strategic acquisition expands Innoviva's portfolio, encompassing potential first- and best-in-class medications for the treatment of multidrug-resistant gram-negative bacteria, including the lead asset SUL-DUR. Entasis Therapeutics Inc. is a US-based biotech company specializing in the development of antibacterial therapeutics aimed at addressing serious infections caused by multidrug-resistant bacteria.

Major players in the multidrug resistant bacteria market are Pfizer Inc., Johnson And Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Lupin Pharmaceuticals Inc., BioMarin Pharmaceuticals Inc., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Alkem Laboratories, Wockhardt Ltd., Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Theravance Biopharma Inc., Melinta Therapeutics Inc., Armata Pharmaceuticals Inc., Tetraphase Pharmaceuticals Inc.

North America was the largest region in the multidrug-resistant bacteria market in 2023. The regions covered in multidrug-resistant bacteria report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the multidrug-resistant bacteria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The multidrug-resistant bacteria market consists of revenues earned by entities by providing services such as infection diagnosis and combination therapy, surgery and antimicrobial stewardship. The market value includes the value of related goods sold by the service provider or included within the service offering. The multidrug-resistant bacteria market also consists of sales of colistin, polymyxins, aminoglycosides, antibiotic synergy kits, monoclonal antibodies and vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Various diseases are caused by multidrug-resistant bacteria, including urinary tract infections, intra-abdominal infections, bloodstream infections, Clostridium difficile infections, acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia, among others. Urinary tract infections, for example, can affect different parts of the urinary system, such as the kidneys, bladder, and ureters. The treatment of these diseases involves the use of various drugs, including oxyazolidinones, lipoglycopeptides, tetracyclines, cephalosporins, combination therapies, and more, administered through oral, parenteral, and other routes. These treatments are provided to patients in various healthcare settings, including hospitals, specialty clinics, homecare, and others.

This report provides multidrug-resistant bacteria market statistics, including multidrug-resistant bacteria industry global market size, regional shares, competitors with a multidrug-resistant bacteria market share, detailed multidrug-resistant bacteria market segments, market trends and opportunities and any further data you may need to thrive in the multidrug-resistant bacteria industry. This multidrug-resistant bacteria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.